Loading organizations...
NPS Pharmaceuticals develops biopharmaceutical treatments for rare gastrointestinal and endocrine disorders. Its notable product, GATTEX (teduglutide [rDNA origin]), addresses Short Bowel Syndrome, showcasing a specialized approach to therapies for underserved patient populations. The company focuses its research and development on innovative solutions for these high medical needs.
Founded in 1986 by Hunter Jackson, NPS Pharmaceuticals emerged with a strategic emphasis on advancing therapeutic options for challenging medical conditions. Jackson's foundational insight centered on the critical need to pursue treatments for diseases often overlooked by larger pharmaceutical firms, establishing the company's dedicated focus on rare disorders.
The company serves patients afflicted with rare conditions, such as Short Bowel Syndrome, by providing targeted medical solutions. NPS Pharmaceuticals’ overarching mission was to ensure that every individual living with a rare disease would ultimately have access to an effective therapy, striving to make a significant, positive impact on their health and daily living.
NPS Pharmaceuticals has raised $5.0M across 1 funding round.
NPS Pharmaceuticals has raised $5.0M in total across 1 funding round.
NPS Pharmaceuticals has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in May 1992.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 1992 | $5M Seed | — | Domain Associates | Announced |
NPS Pharmaceuticals has raised $5.0M in total across 1 funding round.
NPS Pharmaceuticals's investors include Domain Associates.
NPS Pharmaceuticals was a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, particularly in gastrointestinal and endocrine disorders. It built products like GATEX/REVESTIVE (teduglutide) for short bowel syndrome (SBS), a rare GI condition in adults dependent on parenteral support, and advanced NATPARA (rhPTH 1-84) as a hormone replacement for hypoparathyroidism (HPT).[1][2][3] NPS served patients with rare disorders lacking therapeutic options, solving unmet needs through orphan drugs and patient-centric support networks that aided therapy initiation and management.[2][4] The company was acquired by Shire (now Takeda) in 2015, ending its independent operations, with prior growth from its 2013 GATEX launch marking its first commercial success.[3][6]
NPS Pharmaceuticals was founded in 1986, initially exploring various research areas before pivoting.[1][5] Early efforts included CNS, neurology, and cardiovascular discovery, yielding blockbuster products, but by 1999, it acquired Allelix from Toronto, gaining key assets like PTH 1-84 (later NATPARA) and a GLP-2 analog (GATEX).[6] Between 2000-2006, NPS shifted from discovery to development; in 2007, under CEO Francois Nader, it made pivotal strategic moves: repurposing assets for rare diseases, adopting a lean outsourcing model (reducing staff from 280-450 to 35-40), and implementing "culture by design" to emphasize patients.[6] This evolution transformed NPS into a pure-play rare disease biopharma, leading to its 2013 GATEX launch and 2015 acquisition by Shire for its GI and rare disease expertise.[2][3][6]
NPS stood out in biopharma through these key strengths:
NPS rode the rare disease and orphan drug trend, capitalizing on regulatory incentives like accelerated approvals for unmet needs in GI and endocrine areas where few options existed.[1][3][4] Timing was ideal in the 2010s, as biopharma shifted toward high-margin orphan therapies amid blockbuster patent cliffs, with NPS's 2013 GATEX launch proving commercial viability for SBS treatments.[2][3] Market forces like growing rare disease awareness, patient advocacy, and global footprints favored its expansion (e.g., REVESTIVE in Europe).[3] NPS influenced the ecosystem by pioneering patient-centric commercialization, inspiring outsourcing models, and contributing via Shire/Takeda's portfolio—accelerating rare GI therapies while validating acquisitions in biotech consolidation.[3][6]
Post-2015 acquisition by Shire (Takeda), NPS's standalone story ended, but its assets like GATEX and NATPARA endure within Takeda's rare disease portfolio, driving ongoing revenue from SBS and HPT treatments.[3] Trends like precision medicine, gene therapies, and expanded orphan indications will shape their legacy, potentially boosting NATPARA if approvals expand. NPS's influence evolves through Takeda's global scale, reinforcing patient-focused biopharma as a high-growth model—echoing its origin as a rare disease pioneer that transformed lives beyond big pharma norms.[1][2][3]
